Bank of America Securities analyst Craig Bijou has reiterated their bullish stance on SIBN stock, giving a Buy rating today.
Craig Bijou has given his Buy rating due to a combination of factors that highlight SI-Bone’s strong financial performance and growth potential. The company reported a notable 5% revenue beat in the first quarter, with a 25% year-over-year increase, demonstrating robust performance across its portfolio. Additionally, SI-Bone achieved a positive EBITDA of $460k, which exceeded expectations and suggests improving operational efficiency.
Furthermore, the company has shown impressive growth in its sales force productivity and surgeon engagement, with a 27% increase in active surgeons and a record number of procedures by interventionalists. This growth is supported by the launch of new products, including a breakthrough designation product that could significantly impact the orthopedic and spine surgery market. With minimal tariff exposure and a strong domestic manufacturing base, SI-Bone is well-positioned for continued success, justifying the Buy rating.
According to TipRanks, Bijou is a 3-star analyst with an average return of 1.8% and a 44.91% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, RxSight, and Bausch + Lomb Corporation.
In another report released today, Citizens JMP also reiterated a Buy rating on the stock with a $32.00 price target.